{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:18:27Z","timestamp":1764937107338},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10928-019-09661-4","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:31:57Z","timestamp":1572467517000},"page":"605-616","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure\u2013response analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Nikolaos","family":"Tsamandouras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Duvvuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"9661_CR1","unstructured":"FDA (2005) Guidance for Industry. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Silver Spring"},{"issue":"4","key":"9661_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green C, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz R, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97(4):326\u2013335. \nhttps:\/\/doi.org\/10.1002\/cpt.60","journal-title":"Clin Pharmacol Ther"},{"key":"9661_CR3","volume-title":"E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs\u2014questions and answers (R3)","author":"FDA","year":"2017","unstructured":"FDA (2017) E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs\u2014questions and answers (R3). Guidance for Industry, SIlver Spring"},{"issue":"3","key":"9661_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, Mehrotra D, Riley S, Sager P, Tornoe C, Wang Y (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):383\u2013397. \nhttps:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9661_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cpt.361","volume":"100","author":"C Garnett","year":"2016","unstructured":"Garnett C, Needleman K, Liu J, Brundage R, Wang Y (2016) Operational characteristics of linear concentration-QT models for assessing QTc interval in the thorough QT and phase I clinical studies. Clin Pharmacol Ther 100(2):170\u2013178. \nhttps:\/\/doi.org\/10.1002\/cpt.361","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9661_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10928-018-9582-0","volume":"45","author":"J Lu","year":"2018","unstructured":"Lu J, Li J, Helmlinger G, Al-Huniti N (2018) Assessing QT\/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods. J Pharmacokinet Pharmacodyn 45(3):469\u2013482. \nhttps:\/\/doi.org\/10.1007\/s10928-018-9582-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9661_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/jcph.1065","volume":"58","author":"G Ferber","year":"2018","unstructured":"Ferber G, Sun Y, Darpo B, Garnett C, Liu J (2018) Study design parameters affecting exposure response analysis of QT data: results from simulation studies. J Clin Pharmacol 58(5):674\u2013685. \nhttps:\/\/doi.org\/10.1002\/jcph.1065","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-019-09661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-019-09661-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-019-09661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:43:28Z","timestamp":1603845808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-019-09661-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["9661"],"URL":"https:\/\/doi.org\/10.1007\/s10928-019-09661-4","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"26 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are employees and stockholders of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}